Lilly's triple agonist, retatrutide, delivered substantial weight loss and A1C reduction, underscoring its potential promise for people with obesity and type 2 diabetes
PR Newswire•29/09/2026•18:00 ET
0
Key Highlights
- ➤Retatrutide 12 mg delivered 20.8% average weight loss over 80 weeks
- ➤Retatrutide reduced A1C by up to 1.6% on average
- ➤Retatrutide 12 mg: 59.5% no longer met BMI criteria for obesity
- ➤Lilly plans BLA submission to FDA in Q1 2027
Expert Statements
Juan P. Frías, M.D., Medical Director and Principal Investigator, Los Angeles Institute for Metabolic Research
“The vast majority of people with type 2 diabetes are also living with obesity, and treating the two together has always been a challenge. In TRIUMPH-2, retatrutide reduced both weight and blood sugar substantially, with more than half of participants no longer qualifying as having obesity and up to 40% reaching an A1C in the normal range. Results such as these may change what we set out to achieve with a single therapy for adults living with type 2 diabetes and obesity.”
Kenneth Custer, Ph.D., Executive Vice President and President, Lilly Cardiometabolic Health
“TRIUMPH-2 shows what the next generation of cardiometabolic medicine could deliver: substantial weight loss, A1C reduction and improvements across other critical cardiovascular risk factors. With efficacy this powerful and consistent across our Phase 3 program, we believe retatrutide could become an important option for people living with type 2 diabetes and obesity.”
Lilly's triple agonist, retatrutide, delivered substantial weight loss and A1C reduction, underscoring its potential promise for people with obesity and type 2 diabetes PR Newswire
In TRIUMPH-2, participants with obesity and type 2 diabetes taking retatrutide 12 mg lost an average of 49.6 lbs (20.8%) over 80 weeks, with more than half no longer meeting the BMI criteria for obesity
Get started
Create a free account to read the full story.